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Introduction
The human mammary epithelium is the tissue from which
most breast tumours arise. Understanding how processes
such as proliferation and differentiation of the epithelium
are controlled by the ovarian steroids oestradiol and pro-
gesterone may lead to an increased understanding of the
carcinogenic process. The present article reviews some of
what is known about the involvement of the receptors for
oestradiol and progesterone in the normal mammary gland
and in tumorigenesis.
Structure of the human mammary gland
The mammary gland is not completely formed at birth, but
begins to develop in early puberty when the primitive
ductal structures enlarge and branch [1]. Once ovulatory
menstrual cycles have begun, branching of the ductal
system becomes more complex and lobular structures
form at the ends of the terminal ducts to produce terminal
ductal lobular units (TDLUs), which become more complex
with successive menstrual cycles. During early pregnancy,
there is another burst of activity in which the ductal trees
expand further and the number of ductules within the
TDLUs increases greatly. These ductules differentiate to
synthesise and secrete milk in late pregnancy and subse-
quent lactation.
The entire ductal system of the human mammary gland is
lined by a continuous layer of luminal epithelial cells that is,
in turn, surrounded by a layer of myoepithelial cells. These
myoepithelial cells are in direct contact with the basement
membrane, and the TDLUs are surrounded by delimiting
fibroblasts and embedded in a specialised intralobular
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stroma. Histological studies have shown that most human
breast tumours appear to be derived from TDLUs and
have morphological characteristics of luminal epithelial
cells (reviewed in [2]). Moreover, most human breast
tumours retain the biochemical features of luminal cells in
that they express the appropriate cytokeratins and mem-
brane antigens such as MUC-1 [2]. Human tumours also
contain receptors for oestradiol and progesterone that, in
the normal breast, are expressed only in the luminal epithe-
lial cell compartment. Luminal epithelial cells must there-
fore be regarded as the primary targets for malignant
transformation and subsequent tumour formation.
The process of breast tumorigenesis is thought to result
from a ‘benign to malignant’ progression in which the
accumulation of multiple genetic changes allows evolution
from normal breast epithelium through benign proliferative
lesions to atypical proliferative lesions, and then to carci-
noma in situ and frankly invasive tumours. This progres-
sion is elegantly reviewed by Allred and colleagues [3],
who report that the lesions associated with the greatest
risk of invasive breast cancer are hyperplasia of usual type,
atypical ductal hyperplasia, ductal carcinoma in situ
(DCIS) and lobular carcinoma in situ.
Ovarian steroids, breast development and
tumorigenesis
The clinical and epidemiological evidence for an obligate
role of oestrogen in human mammary gland development
and tumorigenesis is considerable. There is complete
failure of breast development in the absence of intact
ovarian function, and oestradiol-replacement therapy is
necessary to induce breast development [4]. Increased
exposure to the fluctuating levels of oestradiol of the
menstrual cycle through early menarche, late menopause
or a late, first, full-term pregnancy increases breast
cancer risk, as does use of exogenous oestrogens in the
form of the oral contraceptive pill or hormone replace-
ment therapy [5]. More compellingly, treatment with anti-
oestrogens reduces the incidence of breast cancer in
high-risk women [6]. The obligate role for oestradiol in
mammary gland development and tumour formation has
been confirmed in studies on mice where the gene for the
ERα has been knocked out [7]. The mammary glands in
these ERα knockout mice comprise rudimentary ducts
confined to the nipple area, which cannot be induced to
develop further with oestradiol treatment and which are
resistant to malignant transformation following transduc-
tion with oncogenes.
There is far less evidence for a role of progesterone in
human breast development. Studies on mouse models in
which the PR has been knocked out suggest that,
whereas oestradiol stimulates ductal elongation and PR
expression, progesterone induces lobuloalveolar develop-
ment [8]. Generally, it is assumed that progesterone plays
a similar role in the human breast and stimulates TDLU for-
mation and expansion during puberty and pregnancy. As
far as is known this has never been demonstrated,
although this might be because it is almost impossible to
study human breast tissue at these stages of develop-
ment. As far as a role for progesterone in breast tumori-
genesis is concerned, there are now some data
suggesting that exogenous progestins taken in the form of
combined hormone replacement therapy increase the risk
of postmenopausal breast cancer to a greater extent than
use of oestrogen replacement therapy alone [9,10].
Effects of oestrogen and progesterone are
mediated by the ER and by the PR
Steroid hormones such as oestradiol and progesterone
are lipophilic and they enter cells and their nuclei primarily
by diffusing through the plasma and nuclear membranes.
Once in the nucleus, the steroids encounter proteins
known as receptors because they bind their cognate
ligands with high affinity and specificity. There are two
receptors for oestradiol, the ERα and the ERβ. Both these
ERs are members of the steroid/thyroid hormone nuclear
receptor superfamily and both may be described as
ligand-dependent nuclear transcription factors. The ER
proteins have the modular structure that typifies the
nuclear receptor superfamily, which includes domains that
mediate binding to ligands and to DNA. Although the two
ERs are homologous in their DNA-binding and steroid-
binding domains, the ERβ gene is smaller, it has a different
chromosomal location and it encodes a shorter protein
[11,12]. The distinctly different but overlapping tissue
distribution of the ERβ compared with the ERα suggests
that it might mediate some of the non-classical effects of
oestrogens and anti-oestrogens. Alternatively, the results of
experimental studies suggest that the ERβ might interact
with and negatively modulate the actions of the ERα [13].
Progesterone also has two receptors, PRA and PRB.
Unlike the ERs, however, these two receptors are trans-
cribed from the same gene via alternative promoter usage.
PRB is longer than PRA as it contains an additional 164
amino acids at its N-terminal, but otherwise the two
proteins are identical [14]. PRA and PRB also are
members of the steroid/thyroid hormone nuclear receptor
superfamily, and they function as ligand-dependent
nuclear transcription factors. It has been suggested that
PRB is the major activator of gene transcription and that
PRA is a repressor of PRB activity [15]. However, more
recent studies on breast cancer cells engineered to
express either PRA or PRB alone [16] or on mice in which
the isoforms have been selectively deleted [17] suggest
that PRA as well as PRB can activate gene transcription.
Moreover, the two isoforms can be differentiated in terms
of the profile of genes that they can activate and by the
fact that PRB, but not PRA, mediates the effects of prog-
esterone on mouse mammary gland development [17].199
ER and PR expression in normal human
breast
Most data on ER and PR expression in the normal human
breast have been obtained in the course of studies on
tissue from adult women who are neither pregnant nor lac-
tating. These studies show that ERα is expressed in
approximately 15–30% of luminal epithelial cells and not
at all in any of the other cell types within the human breast
[18]. Studies on the expression of ERβ in either normal or
malignant human breast epithelium have been hampered
by a lack of antibodies that can reliably detect the protein
in sections of formalin-fixed, paraffin-embedded tissue.
Such antibodies have recently been developed [19],
however, and initial studies indicate that the ERβ is
expressed in most luminal epithelial and myoepithelial
cells, as well as being detectable in fibroblasts and other
stromal cells within the normal human breast [20]. Unfor-
tunately, this widespread distribution is not very informa-
tive as regards the function of the ERβ in the normal breast.
The results of studies on mice in which the ERβ has been
deleted are similarly uninformative as the mammary glands
develop normally in these mice and they appear to have no
difficulty in nursing their young [21]. These data thus
suggest that, despite its more restricted pattern of expres-
sion, the ERα is the key mediator of oestradiol action in the
normal mammary gland and suggest that further studies
are required to establish the role of ERβ.
Most of the investigations where immunohistochemistry
was used to determine the level and distribution of PR
expression in the normal human breast were carried out
before reagents capable of distinguishing the two isoforms
became available. Nevertheless, these studies showed
that, like the ERα, the PR was present in 15–30% of
luminal epithelial cells and not elsewhere in the breast [18].
Dual-label immunofluorescent techniques have been used
to show that all cells expressing the PR also contain the
ERα. In contrast, steroid receptor-expressing cells are
separate from, but often adjacent to, these labelled with
markers of proliferation [18]. This dissociation between
steroid receptor expression and proliferation has been
confirmed by other groups in both human breast and in
rodent mammary glands [22]. The current hypothesis is
that oestradiol and/or progesterone controls the prolifera-
tive activity of luminal epithelial cells indirectly in a mecha-
nism where the receptor-containing cells act as ‘sensors’
that secrete positive or negative paracrine and/or juxta-
crine growth factors, according to the prevailing oestra-
diol/progesterone concentrations, to influence the activity
of nearby division-competent cells. This would attenuate
the sensitivity of the breast epithelium to steroid hormones
such that proliferation will occur only when a sufficient
concentration of positive growth factors has accumulated.
This might be achieved only after prolonged exposure to
high levels of steroid and possibly other hormones, as in
early pregnancy, and may be a mechanism for preventing
excessive proliferative activity at other times.
Relationship between the ER, the PR and
proliferation in tumorigenesis
Increased ERα expression may be one of the very earliest
changes occurring in the tumorigenic process. Khan and
colleagues [23] have shown increased ERα expression in
normal epithelium taken from tumour-bearing breasts. In
addition, ERα expression is higher in the breast tissue of
women from a population at high risk of breast cancer
compared with that in the tissue of Japanese women who
have a relatively low risk of the disease [24]. ERα expres-
sion is increased at the very earliest stages of ductal
hyperplasia and increases still further with increasing
atypia, such that most cells in atypical ductal hyperplasias
and in DCIS of low and intermediate nuclear grade
contain the ERα [3,25]. There are fewer ERα-positive
cells in DCIS of high nuclear grade, but the expression of
markers such as c-erbB-2/HER-2 suggests that these
lesions form a different pathway to invasive cancer.
As ERα expression increases, the inverse relationship
between receptor expression and proliferation becomes
dysregulated. There are increasing numbers of cells
expressing both the ERα and the Ki67 proliferation-
associated antigen with progression toward malignancy,
and this is another early change associated with the
process of breast tumorigenesis [26]. Interestingly, a
proportion of hyperplasias of usual type also contain prolif-
erating ERα-positive cells, and it remains to be seen
whether these lesions are the ones that progress to
invasive tumours. Approximately 70% of invasive breast
carcinomas contain the ERα, and preliminary studies
indicate that most of these tumours contain ERα-positive,
proliferating cells [18]. Clearly, patients whose invasive
tumours contain the ERα are suitable for endocrine
therapy, but there is no evidence that dysregulation of the
relationship between receptor expression and proliferation
has any influence on their response. This is in keeping with
the suggestion that dysregulation is an important step in
early tumorigenesis but is less important at later stages.
There are some data showing that ERβ expression is
downregulated in lesions such as atypical ductal hyperplasia
and DCIS when compared with that in normal breast
epithelium [27]. The same group has shown that the recep-
tor is inversely correlated with proliferation and that the
ratio between the ERα and the ERβ increases with increas-
ing atypia. This is consistent with the suggestion that the
ERβ negatively modulates the effects of the ERα [27]. The
data with regard to ERβ expression in invasive tumours and
its relationship to prognosis or response to endocrine
therapy are somewhat contradictory, with some groups
reporting that the presence of this receptor is a good prog-
nostic factor and others reporting the reverse [28].
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There are a few studies on PR expression in premalignant
and preinvasive lesions, and these few suggest that
expression of the PR also increases with increasing atypia
[3]. There is some evidence suggesting that the ratio
between PRA and PRB is altered during tumorigenesis,
such that PRA predominates [29]. How this can be recon-
ciled with the suggestion that PRA acts as a dominant
repressor of the action of PRB and other steroid receptors
has yet to be determined, but these data suggest that
alteration of the PR isoform ratio also has a role in human
breast tumorigenesis. Approximately 60% of invasive
breast carcinomas express PRA and/or PRB, and PR
expression is regarded generally as a marker of intact ERα
function [3]. Patients whose tumours contain both the
ERα and the PR have the greatest probability of respond-
ing to endocrine therapy and have a better prognosis than
those whose tumours do not contain steroid receptors.
Whether the PR isoform ratio has any bearing on
response to endocrine therapy remains to be determined.
Conclusions
There is almost complete dissociation between steroid
receptor (ERα and PR) expression and proliferation in the
normal human mammary epithelium, suggesting that the
ovarian steroids oestradiol and progesterone control pro-
liferation and development of the mammary gland indi-
rectly via the secretion of paracrine growth factors. This
may be one way of attenuating the sensitivity of the normal
mammary epithelium to the effects of the ovarian steroids
and of ensuring that significant proliferative activity occurs
only when it is needed (i.e. during puberty and pregnancy).
Increased ERα expression and loss of the inverse relation-
ship between steroid receptor expression and proliferation
occurs at the earliest stages of breast tumour develop-
ment, implying that dysregulation of ERα expression is an
important step in the tumorigenic process. Clearly,
enhanced ERα and PR expression would sensitise the
premalignant epithelium to the proliferative effects of their
cognate ligands, but it remains to be determined whether
oestradiol and progesterone continue to drive proliferation
by the indirect mechanisms that exist in the normal epithe-
lium or whether an alternative, more direct, pathway has
arisen during malignant transformation.
Further studies on the mechanisms by which oestradiol
and progesterone control the development of the human
breast and breast tumours could lead to the identification
of new targets for breast cancer prevention, to improved
prediction of invasive breast cancer risk and to early
detection of breast tumours.
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